134 related articles for article (PubMed ID: 24327933)
1. RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.
Eyob H; Ekiz HA; Welm AL
Oncoimmunology; 2013 Sep; 2(9):e25670. PubMed ID: 24327933
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.
Eyob H; Ekiz HA; Derose YS; Waltz SE; Williams MA; Welm AL
Cancer Discov; 2013 Jul; 3(7):751-60. PubMed ID: 23612011
[TBL] [Abstract][Full Text] [Related]
3. Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.
Lai SA; Gundlapalli H; Ekiz HA; Jiang A; Fernandez E; Welm AL
Cancer Discov; 2021 Dec; 11(12):3178-3197. PubMed ID: 34330779
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.
Ekiz HA; Lai SA; Gundlapalli H; Haroun F; Williams MA; Welm AL
Oncoimmunology; 2018; 7(9):e1480286. PubMed ID: 30228950
[TBL] [Abstract][Full Text] [Related]
5. MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity.
Huang L; Fang X; Shi D; Yao S; Wu W; Fang Q; Yao H
Front Immunol; 2020; 11():569082. PubMed ID: 33117355
[TBL] [Abstract][Full Text] [Related]
6. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
Feres KJ; Ischenko I; Hayman MJ
Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
[TBL] [Abstract][Full Text] [Related]
7. The ron receptor tyrosine kinase: a key regulator of inflammation and cancer progression.
Wang X; Hankey PA
Crit Rev Immunol; 2013; 33(6):549-74. PubMed ID: 24266348
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.
Zhao S; Cao L; Freeman JW
Oncogenesis; 2013 Oct; 2(10):e76. PubMed ID: 24100611
[TBL] [Abstract][Full Text] [Related]
9. Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression.
Sullivan C; Brown NE; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
Mol Cancer Res; 2020 Aug; 18(8):1244-1254. PubMed ID: 32439702
[TBL] [Abstract][Full Text] [Related]
10. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.
Cunha S; Lin YC; Goossen EA; DeVette CI; Albertella MR; Thomson S; Mulvihill MJ; Welm AL
Cell Rep; 2014 Jan; 6(1):141-54. PubMed ID: 24388747
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential.
Faham N; Zhao L; Welm AL
NPJ Breast Cancer; 2018; 4():36. PubMed ID: 30456298
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration.
Willett CG; Wang MH; Emanuel RL; Graham SA; Smith DI; Shridhar V; Sugarbaker DJ; Sunday ME
Am J Respir Cell Mol Biol; 1998 Apr; 18(4):489-96. PubMed ID: 9533936
[TBL] [Abstract][Full Text] [Related]
13. HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
Ruiz-Torres SJ; Benight NM; Karns RA; Lower EE; Guan JL; Waltz SE
Oncotarget; 2017 Aug; 8(35):58918-58933. PubMed ID: 28938607
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
[TBL] [Abstract][Full Text] [Related]
15. RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.
Andrade K; Fornetti J; Zhao L; Miller SC; Randall RL; Anderson N; Waltz SE; McHale M; Welm AL
Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123075
[TBL] [Abstract][Full Text] [Related]
16. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
Kretschmann KL; Eyob H; Buys SS; Welm AL
Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
[TBL] [Abstract][Full Text] [Related]
17. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC).
Li C; Morvaridi S; Lam G; Chheda C; Kamata Y; Katsumata M; Edderkaoui M; Yuan X; Nissen N; Pandol SJ; Wang Q
Front Physiol; 2019; 10():147. PubMed ID: 30863319
[TBL] [Abstract][Full Text] [Related]
18. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
Ma Q; Guin S; Padhye SS; Zhou YQ; Zhang RW; Wang MH
Mol Cancer; 2011 May; 10():66. PubMed ID: 21619683
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
